Current Edition

Autoimmune Diseases

Bristol Myers Squibb’s next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny

After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in …

Continue Reading →

Amgen’s Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Some of Amgen’s key businesses are drawing concerns as competition looms. Amgen’s 2022 sales could be about $26.3 billion, or $700 million lower than industry …

Continue Reading →

New Analysis Shows High Rates of Skin Clearance as Measured by Absolute PASI in Patients With Moderate to Severe Plaque Psoriasis Treated With Janssen’s TREMFYA® (guselkumab)

Janssen-Cilag International NV (“Janssen”) presented a new analysis from VOYAGE 1 assessing efficacy responses based on absolute Psoriasis Area and Severity Index score (PASI), as …

Continue Reading →

New Phase 2 Data Show Treatment With Tremfya® (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective antiinterleukin- (IL)-23 monoclonal antibody …

Continue Reading →